Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Hemospan is superior to Voluven for
preventing hypotensive episodes during the perioperative period (from induction of spinal
anesthesia until 6 hours after skin closure), and for reducing the incidence of operative and
postoperative complications including organ dysfunction and failure until follow-up at one
month following surgery. An independent Data Safety Monitoring Board (DSMB) will periodically
evaluate the safety data collected during this trial.